Niagen Bioscience IncNAGE
Price$2.68Intrinsic value$2.9510% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $129.1M+29.6% YoYTTM through 30 Jun 2026
Net Income $16M+87.0% YoYTTM through 30 Jun 2026
Free Cash Flow -$1.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin63.5%
EBITDA Margin8.7%
Operating Margin5.0%
Net Margin12.4%

Returns

22.7%ROE
16.3%ROA
86.8%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.61x
Net Debt-$66.5Mnet cash position
Cash & Equivalents$64.1M

Quality Metrics

Altman Z-Score6.54
Piotroski F-Score6 / 9
FCF Margin-1.0%
Rule of 408.5
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $129.4M
Diluted EPS$0.19TTM
'13'20'21'22'23'24'25
FY2025: $0.20

Dividend

No dividend

Capital Allocation

R&D Spend$6.5M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.